The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 3, Issue 64, Pages 64rv1-64rv1
Publisher
American Association for the Advancement of Science (AAAS)
Online
2011-01-06
DOI
10.1126/scitranslmed.3001366
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
- (2010) J. J. Manfredi GENES & DEVELOPMENT
- Identification and Characterization of the First Small Molecule Inhibitor of MDMX
- (2010) Damon Reed et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
- (2010) Mark Demma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The p53 orchestra: Mdm2 and Mdmx set the tone
- (2010) Mark Wade et al. TRENDS IN CELL BIOLOGY
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- Blinded by the Light: The Growing Complexity of p53
- (2009) Karen H. Vousden et al. CELL
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
- (2009) Ramzi M Mohammad et al. Molecular Cancer
- p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
- (2009) Shu-Ping Wang et al. NATURE CELL BIOLOGY
- p53 Activation: A Case against Sir
- (2008) Christopher L. Brooks et al. CANCER CELL
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
- (2008) Sonia Lain et al. CANCER CELL
- The dark side of a tumor suppressor: anti-apoptotic p53
- (2008) R U Jänicke et al. CELL DEATH AND DIFFERENTIATION
- Does control of mutant p53 by Mdm2 complicate cancer therapy?
- (2008) C. Prives et al. GENES & DEVELOPMENT
- The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
- (2008) T. Terzian et al. GENES & DEVELOPMENT
- Cancer cells suppress p53 in adjacent fibroblasts
- (2008) J Bar et al. ONCOGENE
- TP53 Status and Response to Chemotherapy in Breast Cancer
- (2008) Philippe Bertheau et al. PATHOBIOLOGY
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
- (2008) F. M. Boeckler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started